Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04713371 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial for Patients With Metastatic Solid Cancer
A Phase 2 study of Metastatic Cancer, sponsored by Rampart Health, L.L.C..
- Active
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT04713371: Active Phase 2 study of Metastatic Cancer, sponsored by Rampart Health, L.L.C..
NCT04713371 is a Phase 2 study of Metastatic Cancer that is active but no longer recruiting, run by Rampart Health, L.L.C.. The registered enrollment target is 32 participants, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04713371, a Phase 2 study of Metastatic Cancer, is active but no longer recruiting, sponsored by Rampart Health, L.L.C..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This study seeks to estimate the potential efficacy of the study treatment, as well as the occurrence of adverse events.
Conditions Studied
Interventions
- DRUG Cytoxan
- DRUG Keytruda Injectable Product
- DRUG Yervoy Injectable Product
- PROCEDURE Cryosurgical freezing (cryosurgery)
- DRUG GM-CSF Injectable
Study Locations (1)
Michigan
- Ascension Providence Rochester Hospital - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-05-19 |
| Est. Completion | 2024-12 |
| Phase | Phase 2 |
What the registry record for NCT04713371 still lists
NCT04713371 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Metastatic Cancer appearing as the primary indexed condition, and to 5 interventions - of which Cytoxan is the first listed.
NCT04713371 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT04713371 about?
NCT04713371 is a clinical study titled "A Phase 2 Trial for Patients With Metastatic Solid Cancer". This study seeks to estimate the potential efficacy of the study treatment, as well as the occurrence of adverse events.
What is the current status of trial NCT04713371?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2021-05-19. Estimated completion is 2024-12.
What conditions does trial NCT04713371 study?
This clinical trial studies the following conditions: Metastatic Cancer.
What interventions are being tested in trial NCT04713371?
The interventions under investigation include: Cytoxan (DRUG), Keytruda Injectable Product (DRUG), Yervoy Injectable Product (DRUG), Cryosurgical freezing (cryosurgery) (PROCEDURE), GM-CSF Injectable (DRUG).
Who is sponsoring clinical trial NCT04713371?
This trial is sponsored by Rampart Health, L.L.C., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04713371 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04713371's enrollment target sits among peer trials
32 78th of 109 higher than 31 of 109 other Metastatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Biomarkers to Detect Endocrine Therapy Resistance
RECRUITING · Phase 2
-
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
RECRUITING · Phase 2
-
Definitive Radiation for High-Risk Spine Metastases
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI